PT2408775E - Derivados oxidados de triazolil purinas úteis como ligandos do recetor a2a de adenosina e a sua utilização como medicamentos - Google Patents
Derivados oxidados de triazolil purinas úteis como ligandos do recetor a2a de adenosina e a sua utilização como medicamentos Download PDFInfo
- Publication number
- PT2408775E PT2408775E PT107095267T PT10709526T PT2408775E PT 2408775 E PT2408775 E PT 2408775E PT 107095267 T PT107095267 T PT 107095267T PT 10709526 T PT10709526 T PT 10709526T PT 2408775 E PT2408775 E PT 2408775E
- Authority
- PT
- Portugal
- Prior art keywords
- triazolylpurines
- adenosine
- medicaments
- ligands
- receptor
- Prior art date
Links
- 102000007471 Adenosine A2A receptor Human genes 0.000 title 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09155690 | 2009-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2408775E true PT2408775E (pt) | 2015-08-05 |
Family
ID=40941572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107095267T PT2408775E (pt) | 2009-03-20 | 2010-03-18 | Derivados oxidados de triazolil purinas úteis como ligandos do recetor a2a de adenosina e a sua utilização como medicamentos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9133197B2 (pt) |
| EP (1) | EP2408775B1 (pt) |
| JP (1) | JP5648044B2 (pt) |
| AR (1) | AR075894A1 (pt) |
| DK (1) | DK2408775T3 (pt) |
| ES (1) | ES2542555T3 (pt) |
| HR (1) | HRP20150766T1 (pt) |
| HU (1) | HUE025704T2 (pt) |
| PL (1) | PL2408775T3 (pt) |
| PT (1) | PT2408775E (pt) |
| SI (1) | SI2408775T1 (pt) |
| SM (1) | SMT201500174B (pt) |
| TW (1) | TWI473809B (pt) |
| WO (1) | WO2010106145A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
| JP7433910B2 (ja) | 2017-06-22 | 2024-02-20 | ノバルティス アーゲー | Ｃｄ７３に対する抗体分子及びその使用 |
| KR102254660B1 (ko) * | 2017-09-28 | 2021-05-24 | 씨스톤 파마슈티컬즈 (상하이) 컴퍼니 리미티드 | Ａ2ａ수용체 억제제로서의 축합 고리 유도체 |
| WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| EP3717907A1 (en) | 2017-11-30 | 2020-10-07 | Novartis AG | Bcma-targeting chimeric antigen receptor, and uses thereof |
| AU2019235842B2 (en) | 2018-03-14 | 2022-02-03 | Surface Oncology, Inc. | Antibodies that bind CD39 and uses thereof |
| TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3802611A2 (en) | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP3924054A1 (en) | 2019-02-15 | 2021-12-22 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| BR112022002351A2 (pt) | 2019-09-16 | 2022-07-19 | Surface Oncology Inc | Composições e métodos de anticorpo anti-cd39 |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| MX2022003719A (es) | 2019-09-25 | 2022-04-26 | Surface Oncology Inc | Anticuerpos anti-il-27 y sus usos. |
| CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| CA3199095A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
| WO2022162569A1 (en) | 2021-01-29 | 2022-08-04 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3990061B2 (ja) * | 1998-01-05 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤 |
| ATE242775T1 (de) | 1998-01-05 | 2003-06-15 | Eisai Co Ltd | Purinderivate und antagonisten des adenosin-a2- rezeptors, welche zur vorsorge oder heilung von diabetes dienen |
| CA2376835C (en) * | 1999-07-02 | 2009-09-15 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| AU3812401A (en) * | 2000-02-10 | 2001-08-20 | Univ New York | Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver |
| KR100897219B1 (ko) * | 2001-06-29 | 2009-05-14 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ２ｂ 아데노신 수용체 길항제로서의 퓨린 유도체 |
| ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| JPWO2003020723A1 (ja) * | 2001-08-30 | 2004-12-16 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体 |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| WO2006129626A1 (ja) * | 2005-05-30 | 2006-12-07 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法 |
-
2010
- 2010-03-18 SI SI201030983T patent/SI2408775T1/sl unknown
- 2010-03-18 JP JP2012500259A patent/JP5648044B2/ja not_active Expired - Fee Related
- 2010-03-18 DK DK10709526.7T patent/DK2408775T3/en active
- 2010-03-18 EP EP10709526.7A patent/EP2408775B1/en active Active
- 2010-03-18 WO PCT/EP2010/053554 patent/WO2010106145A1/en active Application Filing
- 2010-03-18 HU HUE10709526A patent/HUE025704T2/en unknown
- 2010-03-18 PL PL10709526T patent/PL2408775T3/pl unknown
- 2010-03-18 US US13/257,750 patent/US9133197B2/en not_active Expired - Fee Related
- 2010-03-18 ES ES10709526.7T patent/ES2542555T3/es active Active
- 2010-03-18 PT PT107095267T patent/PT2408775E/pt unknown
- 2010-03-19 AR ARP100100883A patent/AR075894A1/es unknown
- 2010-03-19 TW TW99108187A patent/TWI473809B/zh not_active IP Right Cessation
-
2015
- 2015-07-13 HR HRP20150766TT patent/HRP20150766T1/hr unknown
- 2015-07-20 SM SM201500174T patent/SMT201500174B/xx unknown
- 2015-08-10 US US14/822,252 patent/US20160002244A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SMT201500174B (it) | 2015-10-30 |
| US20120053191A1 (en) | 2012-03-01 |
| PL2408775T3 (pl) | 2015-10-30 |
| EP2408775A1 (en) | 2012-01-25 |
| JP2012520854A (ja) | 2012-09-10 |
| US9133197B2 (en) | 2015-09-15 |
| WO2010106145A1 (en) | 2010-09-23 |
| TWI473809B (zh) | 2015-02-21 |
| EP2408775B1 (en) | 2015-06-17 |
| DK2408775T3 (en) | 2015-07-27 |
| US20160002244A1 (en) | 2016-01-07 |
| ES2542555T3 (es) | 2015-08-06 |
| HRP20150766T1 (hr) | 2015-08-14 |
| TW201100425A (en) | 2011-01-01 |
| AR075894A1 (es) | 2011-05-04 |
| SI2408775T1 (sl) | 2015-08-31 |
| JP5648044B2 (ja) | 2015-01-07 |
| HUE025704T2 (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2408775E (pt) | Derivados oxidados de triazolil purinas úteis como ligandos do recetor a2a de adenosina e a sua utilização como medicamentos | |
| IL250435A0 (en) | Using hil-2-mutein of human origin to prepare a factor for the production of regulatory t cells | |
| SI2552909T1 (sl) | Derivati 4-aminopirimidina in njihova uporaba kot antagonisti receptorja adenozin A2A | |
| IL221160A (en) | 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation | |
| ZA201206062B (en) | Aminotetraline derivatives,pharmaceutical compositions containing them,and their use in therapy | |
| HK1153926A1 (en) | Purin derivatives for use in the treatment of fab-related diseases fab- | |
| ZA201000075B (en) | Purin derivatives for use in the treatment of fab-related diseases | |
| IL217490A (en) | History of pyridine-4-il, pharmaceutical preparations containing them and their use in the preparation of medicines | |
| IL216609A0 (en) | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | |
| HK1167392A1 (en) | Adenosine receptor ligands and uses thereof | |
| ZA201004227B (en) | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions | |
| ZA201002959B (en) | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 | |
| EP2188295A4 (en) | PYRIDINE DERIVATIVES AND METHODS OF USE | |
| IL219120A (en) | Cyclohaphtha pyridinyl derivatives and their use in drug preparation | |
| IL215690A0 (en) | Thiazole derivatives and their use as p2y12 receptor antagonists | |
| IL205608A (en) | History of s-triazole-1-ram-benzamide and their use in the preparation of pain medication | |
| IL219888A0 (en) | Pyridine-pyridinone derivatives, preparation and therapeutic use thereof | |
| HK1169388A1 (en) | 6,7,8,9-tetrahydro-pyrimido1,2-a pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof 6789-12-a -4- | |
| EP2448944A4 (en) | Isomannide derivatives and their use as flavorings | |
| EP2621898A4 (en) | PROCESS FOR THE PREPARATION OF TETRACYCLIC DERIVATIVES AND INTERMEDIATE PRODUCTS USED IN THE PROCESS | |
| ZA201107883B (en) | Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containint these derivatives | |
| ZA201104945B (en) | Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds | |
| IL219335A0 (en) | Alkyl substituted arylindenopyrimidines and their use as highly selective adennosine a2a receptor antsgonists | |
| HK1164861A1 (en) | Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof | |
| EP2363132A4 (en) | USE OF SOPHORICOSIDE IN DRUG MANUFACTURE |